Gilead's pipeline focus: any signs of impending RIFs?

Lurking here for a while, and the talk about Gilead's strategic shifts has me wondering. With the recent clinical trial updates and the ongoing focus on certain therapeutic areas, I'm trying to gauge if this signals any larger organizational changes. It feels like there's a pivot happening, and I'm curious if anyone has a gut feeling or has seen indicators that might suggest upcoming reductions in force (RIFs) in specific departments or project teams. I'm not asking for insider info that's not public, but more about observing patterns – are certain roles or skill sets becoming less of a priority based on the company's stated direction? Any thoughts or observations from colleagues across different functions would be appreciated.